Nova Eye Medical LtdASX: EYE

AGM 2026 Presentation

· Issued by Nova Eye Medical Ltd via ASX

Filed with ASX · · 23 pages · English

Summary by 6ix AI

The presentation highlights four consecutive years of strong revenue growth and discusses the interventional glaucoma market's potential. The company confirms its sales guidance for the fiscal year and emphasizes its positive cash flow and EBITDA outlook.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/agm-2026-presentation-1

Watch Nova Eye Medical's latest callNova Eye Medical (ASX:EYE) Q4 2026 Earnings Call · Replay · Aug 3Read the transcript of Nova Eye Medical (ASX:EYE) Q4 2026 Earnings Call

Release

Nova Eye Medical Limited (ASX: EYE) 2026 Annual General Meeting | 29 October 2026 | Tom Spurling, Managing Director Disclaimer This presentation has been prepared by Nova Eye Medical Limited (ASX: EYE). While the information in this presentation has been prepared in good faith and with reasonable...

Nova Eye Medical Ltd on 6ix

In the deck

Story so far

Earlier from Nova Eye Medical

Later from Nova Eye Medical

All Nova Eye Medical news releases